Results of Operations and Financial Condition. On July 9, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended May 31, 2026. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Regulation FD Disclosure. On June 7, 2026, Nurix issued a press release announcing (i) Nurix’s entry into the Collaboration Agreement and (ii) that on June 8, 2026, at 8:00 a.m. Eastern Time, Nurix will host a conference call and webcast to discuss the collaboration between Nurix and Roche. The live webcast, with an accompanying presentation, will be accessible under the Events and Presentations page in the Investors section of Nurix’s website. A replay of the call and webcast will be archive…

Entry into a Material Definitive Agreement. On June 6, 2026, Nurix Therapeutics, Inc. (“ Nurix ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”), dated as of June 8, 2026, with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (collectively, “ Roche ”), pursuant to which Nurix will grant Roche an exclusive worldwide license, including with respect to Nurix and its affiliates, under certain Nurix intellectual property rights to develop, manufacture, commercial…

Results of Operations and Financial Condition. On April 8, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 28, 2026. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Other Events. As previously disclosed, on August 4, 2021, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”), which Equity Distribution Agreement was subsequently amended by Amendment No. 1 to the Equity Distribution Agreement on July 11, 2024 in connection with the filing by the Company of a new universal automatic shelf registration statement on Form…

Results of Operations and Financial Condition. On January 28, 2026, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter and year ended November 30, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchang…

Director — Roger Dansey, M.D.: Dr. Roger Dansey was appointed as a director and member of the Clinical and Commercialization Committee.

Other Events. On October 22, 2025, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC and Stifel, Nicolaus & Company, Incorporated as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of 24,485,799 shares of its common stock (the “Shares”) to the Underwriters (the “Offering…

Results of Operations and Financial Condition. On October 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Class III director and chair of the Clinical and Commercialization Committee — Lori A. Kunkel, M.D.: Dr. Kunkel resigned from her roles on the board and committees.

Results of Operations and Financial Condition. On July 9, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended May 31, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as ame…

Results of Operations and Financial Condition. On April 8, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended February 28, 2025. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,…

Director — Roy D. Baynes, MB.Bch., M.Med., Ph.D.: Dr. Roy D. Baynes was appointed as a new director of the company.

Results of Operations and Financial Condition. On January 28, 2025, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2024. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On January 13, 2025, Nurix Therapeutics, Inc. (the “Company”) will present an investor presentation at the 43rd Annual J.P. Morgan Healthcare Conference (the “JPM Conference”), which reports the preliminary, unaudited amount of the Company’s cash, cash equivalents and marketable securities position as of November 30, 2024, as $609.6 million, and reports that, based on its current operating plan, the Company expects that it will be able to fund it…

Other Events. As previously disclosed, on August 4, 2021, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Piper Sandler & Co. (“Piper Sandler”), which Equity Distribution Agreement was subsequently amended by Amendment No. 1 to the Equity Distribution Agreement entered into by the Company and Piper Sandler on July 11, 2024, in connection with the filing by the Company of a new universal…

Director — Anil Kapur: Anil Kapur was appointed as a director and member of the Development Advisory Committee.

Results of Operations and Financial Condition. On October 11, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended August 31, 2024. The press rele ase is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 19…

Results of Operations and Financial Condition. On July 11, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended May 31, 2024. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…

Entry into a Material Definitive Agreement. On April 11, 2024, Nurix Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Piper Sandler & Co. and Stifel, Nicolaus & Company, Incorporated, as the representatives of the several underwriters named in Schedule 1 thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 10,166,667 shares of its common stock (the “Shar…

Results of Operations and Financial Condition. On April 10, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal quarter ended February 29, 2024. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…

Results of Operations and Financial Condition. On February 15, 2024, Nurix Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing the Company’s financial results for the fiscal year ended November 30, 2023. The press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information furnished with this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…